<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627950</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10498</org_study_id>
    <nct_id>NCT02627950</nct_id>
  </id_info>
  <brief_title>Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction</brief_title>
  <acronym>MonAMI</acronym>
  <official_title>Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current prospective, randomized, controlled MonAMI trial aims to systematically examine
      the effects of morphine on the platelet inhibitory effects of the orally administered
      platelet inhibitor ticagrelor in patients with acute myocardial infarction. In addition, the
      potential positive or negative effects of MCP in combination with morphine on platelet
      inhibition will be studied.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet activity 2 hours after administration of loading dose of ticagrelor measured by VerifyNow-P2Y12-test</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity 0.5, 1, 4, 6 and 24 hours after loading dose of ticagrelor measured by VerifyNow-P2Y12-test</measure>
    <time_frame>0.5, 1, 4, 6 h and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor measured by Vasodilator Stimulated Phosphoprotein-test</measure>
    <time_frame>0.5, 1, 2, 4, 6 h and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with high on-treatment platelet reactivity 0.5, 1, 2, 4, 6 and 24 hours after loading dose of ticagrelor (measured by VerifyNow-P2Y12-test)</measure>
    <time_frame>0.5, 1, 2, 4, 6 h and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ticagrelor plasma levels and levels of active serum metabolites after 0.5, 1, 2, 4, 6 and 24 hours</measure>
    <time_frame>0.5, 1, 2, 4, 6 h and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size measured by delayed enhancement magnetic resonance imaging</measure>
    <time_frame>Day 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction measured by delayed enhancement magnetic resonance imaging</measure>
    <time_frame>Day 1-4</time_frame>
    <description>Cardiac magnetic resonance imaging equivalent of angiographic no-reflow, expressed as percentage of left ventricular mass</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Isotonic sodium chloride + Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor + Metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphinhydrochloricum</intervention_name>
    <description>5 mg morphine intravenously</description>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor</arm_group_label>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor + Metoclopramide</arm_group_label>
    <other_name>Morphin-hameln (manufacturer: hameln pharmaceuticals)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>10 mg MCP intravenously</description>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor + Metoclopramide</arm_group_label>
    <other_name>MCP-ratiopharm (manufacturer: Ratiopharm)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>180 mg ticagrelor orally</description>
    <arm_group_label>Isotonic sodium chloride + Ticagrelor</arm_group_label>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor</arm_group_label>
    <arm_group_label>Morphinhydrochloricum + Ticagrelor + Metoclopramide</arm_group_label>
    <other_name>Brilique (manufacturer: AstraZeneca)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic sodium chloride</intervention_name>
    <description>10 ml NaCl 0.9% intravenously</description>
    <arm_group_label>Isotonic sodium chloride + Ticagrelor</arm_group_label>
    <other_name>NaCl (manufacturer: Berlin-Chemie Menarini)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ST-elevation myocardial infarction &lt; 24 h after symptom onset or non-ST-elevation
             myocardial infarction with persistent chest pain &lt; 24 h after symptom onset

          2. Intended revascularization by primary percutaneous coronary intervention

          3. Informed consent

          4. Age â‰¥18 years

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Active bleeding or bleeding diathesis

          3. Oral anticoagulation

          4. Current treatment with
             clopidogrel/prasugrel/ticagrelor/glycoprotein-IIb-IIIa-receptor-antagonists

          5. Current treatment with morphine and/or MCP &lt;12 h

          6. Contraindication for treatment with platelet inhibitors

          7. Fibrinolysis &lt;48 h

          8. Percutaneous coronary intervention or coronary artery bypass grafting &lt;3 months

          9. Known glomerular filtration rate &lt;30 ml/min

         10. Severe liver dysfunction

         11. Hypersensitivity to ticagrelor or any excipients

         12. History of intracranial hemorrhage

         13. Known pregnancy, breast-feeding or intend to become pregnant during the study period

         14. Participation in other trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele</last_name>
      <email>holger.thiele@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Roza Meyer-Saraei</last_name>
      <email>roza.meyer-saraei@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Holger Thiele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Holger Thiele</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

